Clinical and Experimental Pediatrics

대한소아청소년과학회 (The Korean Pediatric Society)
권호 표지
DOI QR코드

DOI QR Code

Predictive value of C-reactive protein in response to macrolides in children with macrolide-resistant Mycoplasma pneumoniae pneumonia

  • Seo, Young Ho (Department of Pediatrics, Korea University College of Medicine) ;
  • Kim, Jang Su (Department of Laboratory Medicine, Korea University College of Medicine) ;
  • Seo, Sung Chul (Environmental Health Center for Childhood Asthma, Korea University Anam Hospital) ;
  • Seo, Won Hee (Department of Pediatrics, Korea University College of Medicine) ;
  • Yoo, Young (Department of Pediatrics, Korea University College of Medicine) ;
  • Song, Dae Jin (Department of Pediatrics, Korea University College of Medicine) ;
  • Choung, Ji Tae (Department of Pediatrics, Korea University College of Medicine)
  • 투고 : 2013.08.09
  • 심사 : 2013.11.18
  • 발행 : 2014.04.15
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: The prevalence of macrolide-resistant Mycoplasma pneumoniae (MRMP) has increased worldwide. The aim of this study was to estimate the proportion of MRMP in a tertiary hospital in Korea, and to find potential laboratory markers that could be used to predict the efficacy of macrolides in children with MRMP pneumonia. Methods: A total of 95 patients with M. pneumoniae pneumonia were enrolled in this study. Detection of MRMP was based on the results of specific point mutations in domain V of the 23S rRNA gene. The medical records of these patients were reviewed retrospectively and the clinical course and laboratory data were compared. Results: The proportion of patients with MRMP was 51.6% and all MRMP isolates had the A2063G point mutation. The MRMP group had longer hospital stay and febrile period after initiation of macrolides. The levels of serum C-reactive protein (CRP) and interleukin-18 in nasopharyngeal aspirate were significantly higher in patients who did not respond to macrolide treatment. CRP was the only significant factor in predicting the efficacy of macrolides in patients with MRMP pneumonia. The area under the curve for CRP was 0.69 in receiver operating characteristic curve analysis, indicating reasonable discriminative power, and the optimal cutoff value was 40.7 mg/L. Conclusion: The proportion of patients with MRMP was high, suggesting that the prevalence of MRMP is rising rapidly in Korea. Serum CRP could be a useful marker for predicting the efficacy of macrolides and helping clinicians make better clinical decisions in children with MRMP pneumonia.

키워드

참고문헌

  1. Lee KY. Pediatric respiratory infections by Mycoplasma pneumoniae. Expert Rev Anti Infect Ther 2008;6:509-21. https://doi.org/10.1586/14787210.6.4.509
  2. Morozumi M, Takahashi T, Ubukata K. Macrolide-resistant Mycoplasma pneumoniae: characteristics of isolates and clinical aspects of community-acquired pneumonia. J Infect Chemother 2010;16:78-86. https://doi.org/10.1007/s10156-009-0021-4
  3. Suzuki S, Yamazaki T, Narita M, Okazaki N, Suzuki I, Andoh T, et al. Clinical evaluation of macrolide-resistant Mycoplasma pneumoniae. Antimicrob Agents Chemother 2006;50:709-12. https://doi.org/10.1128/AAC.50.2.709-712.2006
  4. Morozumi M, Iwata S, Hasegawa K, Chiba N, Takayanagi R, Matsubara K, et al. Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia. Antimicrob Agents Chemother 2008;52:348-50. https://doi.org/10.1128/AAC.00779-07
  5. Atkinson TP, Boppana S, Theos A, Clements LS, Xiao L, Waites K. Stevens-Johnson syndrome in a boy with macrolide-resistant Mycoplasma pneumoniae pneumonia. Pediatrics 2011;127:e1605-9. https://doi.org/10.1542/peds.2010-2624
  6. Hsieh YC, Tsao KC, Huang CG, Tong S, Winchell JM, Huang YC, et al. Life-threatening pneumonia caused by macrolide-resistant Mycoplasma pneumoniae. Pediatr Infect Dis J 2012;31:208-9. https://doi.org/10.1097/INF.0b013e318234597c
  7. Okada T, Morozumi M, Tajima T, Hasegawa M, Sakata H, Ohnari S, et al. Rapid effectiveness of minocycline or doxycycline against macrolide-resistant Mycoplasma pneumoniae infection in a 2011 outbreak among Japanese children. Clin Infect Dis 2012;55:1642-9. https://doi.org/10.1093/cid/cis784
  8. Lee KY, Lee HS, Hong JH, Lee MH, Lee JS, Burgner D, et al. Role of prednisolone treatment in severe Mycoplasma pneumoniae pneumonia in children. Pediatr Pulmonol 2006;41:263-8. https://doi.org/10.1002/ppul.20374
  9. Ieven M, Ursi D, Van Bever H, Quint W, Niesters HG, Goossens H. Detection of Mycoplasma pneumoniae by two polymerase chain reactions and role of M. pneumoniae in acute respiratory tract infections in pediatric patients. J Infect Dis 1996;173:1445-52. https://doi.org/10.1093/infdis/173.6.1445
  10. Kawai Y, Miyashita N, Yamaguchi T, Saitoh A, Kondoh E, Fujimoto H, et al. Clinical efficacy of macrolide antibiotics against genetically determined macrolide-resistant Mycoplasma pneumoniae pneumonia in paediatric patients. Respirology 2012;17:354-62. https://doi.org/10.1111/j.1440-1843.2011.02102.x
  11. Okazaki N, Narita M, Yamada S, Izumikawa K, Umetsu M, Kenri T, et al. Characteristics of macrolide-resistant Mycoplasma pneumoniae strains isolated from patients and induced with erythromycin in vitro. Microbiol Immunol 2001;45:617-20. https://doi.org/10.1111/j.1348-0421.2001.tb01293.x
  12. Cardinale F, Chironna M, Dumke R, Binetti A, Daleno C, Sallustio A, et al. Macrolide-resistant Mycoplasma pneumoniae in paediatric pneumonia. Eur Respir J 2011;37:1522-4. https://doi.org/10.1183/09031936.00172510
  13. Xin D, Mi Z, Han X, Qin L, Li J, Wei T, et al. Molecular mechanisms of macrolide resistance in clinical isolates of Mycoplasma pneumoniae from China. Antimicrob Agents Chemother 2009;53:2158-9. https://doi.org/10.1128/AAC.01563-08
  14. Wu PS, Chang LY, Lin HC, Chi H, Hsieh YC, Huang YC, et al. Epidemiology and clinical manifestations of children with macrolideresistant Mycoplasma pneumoniae pneumonia in Taiwan. Pediatr Pulmonol 2013;48:904-11. https://doi.org/10.1002/ppul.22706
  15. Pereyre S, Charron A, Renaudin H, Bebear C, Bebear CM. First report of macrolide-resistant strains and description of a novel nucleotide sequence variation in the P1 adhesin gene in Mycoplasma pneumoniae clinical strains isolated in France over 12 years. J Clin Microbiol 2007;45:3534-9. https://doi.org/10.1128/JCM.01345-07
  16. Dumke R, von Baum H, Luck PC, Jacobs E. Occurrence of macrolideresistant Mycoplasma pneumoniae strains in Germany. Clin Microbiol Infect 2010;16:613-6. https://doi.org/10.1111/j.1469-0691.2009.02968.x
  17. Yamada M, Buller R, Bledsoe S, Storch GA. Rising rates of macrolideresistant Mycoplasma pneumoniae in the central United States. Pediatr Infect Dis J 2012;31:409-11. https://doi.org/10.1097/INF.0b013e318247f3e0
  18. Chironna M, Sallustio A, Esposito S, Perulli M, Chinellato I, Di Bari C, et al. Emergence of macrolide-resistant strains during an outbreak of Mycoplasma pneumoniae infections in children. J Antimicrob Chemother 2011;66:734-7. https://doi.org/10.1093/jac/dkr003
  19. Averbuch D, Hidalgo-Grass C, Moses AE, Engelhard D, Nir-Paz R. Macrolide resistance in Mycoplasma pneumoniae, Israel, 2010. Emerg Infect Dis 2011;17:1079-82. https://doi.org/10.3201/eid/1706.101558
  20. Yoo SJ, Kim HB, Choi SH, Lee SO, Kim SH, Hong SB, et al. Differences in the frequency of 23S rRNA gene mutations in Mycoplasma pneumoniae between children and adults with community-acquired pneumonia: clinical impact of mutations conferring macrolide resistance. Antimicrob Agents Chemother 2012;56:6393-6. https://doi.org/10.1128/AAC.01421-12
  21. Oh CE, Choi EH, Lee HJ. Detection of genetic mutations associated with macrolide resistance of Mycoplasma pneumoniae. Korean J Pediatr 2010;53:178-83. https://doi.org/10.3345/kjp.2010.53.2.178
  22. Bebear C, Pereyre S, Peuchant O. Mycoplasma pneumoniae: susceptibility and resistance to antibiotics. Future Microbiol 2011;6: 423-31. https://doi.org/10.2217/fmb.11.18
  23. Narita M, Tanaka H, Abe S, Yamada S, Kubota M, Togashi T. Close association between pulmonary disease manifestation in Mycoplasma pneumoniae infection and enhanced local production of interleukin- 18 in the lung, independent of gamma interferon. Clin Diagn Lab Immunol 2000;7:909-14.
  24. Narita M, Tanaka H. Cytokines involved in the severe manifestations of pulmonary diseases caused by Mycoplasma pneumoniae. Pediatr Pulmonol 2007;42:397. https://doi.org/10.1002/ppul.20445
  25. Oishi T, Narita M, Matsui K, Shirai T, Matsuo M, Negishi J, et al. Clinical implications of interleukin-18 levels in pediatric patients with Mycoplasma pneumoniae pneumonia. J Infect Chemother 2011;17:803-6. https://doi.org/10.1007/s10156-011-0265-7
  26. Tagliabue C, Salvatore CM, Techasaensiri C, Mejias A, Torres JP, Katz K, et al. The impact of steroids given with macrolide therapy on experimental Mycoplasma pneumoniae respiratory infection. J Infect Dis 2008;198:1180-8. https://doi.org/10.1086/591915
  27. Hirao S, Wada H, Nakagaki K, Saraya T, Kurai D, Mikura S, et al. Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone. FEMS Immunol Med Microbiol 2011;62:182-9. https://doi.org/10.1111/j.1574-695X.2011.00799.x

피인용 문헌

  1. Relationships between Th1/Th2 cytokine profiles and chest radiographic manifestations in childhood Mycoplasma pneumoniae pneumonia vol.12, pp.None, 2014, https://doi.org/10.2147/tcrm.s121928
  2. Decreased Interleukin-10 Responses in Children with Severe Mycoplasma pneumoniae Pneumonia vol.11, pp.1, 2014, https://doi.org/10.1371/journal.pone.0146397
  3. Two case reports: Whole genome sequencing of two clinical macrolide-resistant Mycoplasma pneumoniae isolates with different responses to azithromycin vol.95, pp.38, 2014, https://doi.org/10.1097/md.0000000000004963
  4. Clinical features according to chest radiologic patterns of Mycoplasma pneumonia in children vol.33, pp.2, 2014, https://doi.org/10.12701/yujm.2016.33.2.98
  5. Mycoplasma pneumoniae -associated mild encephalitis/encephalopathy with a reversible splenial lesion: report of two pediatric cases and a comprehensive literature review vol.16, pp.None, 2016, https://doi.org/10.1186/s12879-016-1985-1
  6. Effects of methylprednisolone or immunoglobulin when added to standard treatment with intravenous azithromycin for refractory Mycoplasma pneumoniae pneumonia in children vol.13, pp.4, 2014, https://doi.org/10.1007/s12519-017-0014-9
  7. Prediction of Refractory Mycoplasma Pneumoniae Pneumonia in Pediatric Patients vol.30, pp.2, 2014, https://doi.org/10.1089/ped.2016.0732
  8. Macrolide Resistance and Its Impacts on M. Pneumoniae Pneumonia in Children: Comparison of Two Recent Epidemics in Korea vol.9, pp.4, 2017, https://doi.org/10.4168/aair.2017.9.4.340
  9. Mechanism of resistance acquisition and treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children vol.60, pp.6, 2017, https://doi.org/10.3345/kjp.2017.60.6.167
  10. Mycoplasma pneumoniae from the Respiratory Tract and Beyond vol.30, pp.3, 2017, https://doi.org/10.1128/cmr.00114-16
  11. Literature review and future strategies of childhood respiratory diseases in Korea vol.6, pp.suppl1, 2018, https://doi.org/10.4168/aard.2018.6.s1.s66
  12. Current usage and effects of steroids in the management of childhood mycoplasma pneumonia in a secondary hospital vol.6, pp.2, 2014, https://doi.org/10.4168/aard.2018.6.2.122
  13. Increased procalcitonin level is a risk factor for prolonged fever in children with Mycoplasma pneumonia vol.61, pp.8, 2014, https://doi.org/10.3345/kjp.2018.61.8.258
  14. Antimicrobial susceptibility and genotyping of Mycoplasma pneumoniae isolates in Beijing, China, from 2014 to 2016 vol.8, pp.1, 2014, https://doi.org/10.1186/s13756-019-0469-7
  15. Real-Time PCR and Quantitative Culture for Mycoplasma pneumoniae Load in Pharyngeal Swabs from Children at Preliminary Diagnosis and Discharge vol.2020, pp.None, 2014, https://doi.org/10.1155/2020/9814916
  16. Baicalin relieves Mycoplasma pneumoniae infection‑induced lung injury through regulating microRNA‑221 to inhibit the TLR4/NF‑κB signaling pathway vol.24, pp.2, 2021, https://doi.org/10.3892/mmr.2021.12210
  17. Genotype and mutation patterns of macrolide resistance genes of Mycoplasma pneumoniae from children with pneumonia in Qingdao, China, in 2019 vol.27, pp.None, 2014, https://doi.org/10.1016/j.jgar.2021.10.003